Just published, “Gene Therapy Implications for Retina Specialists: Evolving endpoints, novel orphan disease treatment paradigms, and the dawn of precision medicine.” The approval and launch of Spark’s LUXTURNA (voretigene neparvovec-ryzl), the first FDA-approved gene therapy for a genetic disease, introduces novel paradigms to clinical practice, […]
Month: February 2019
Recently co-authored with Enoch Kassa, Rehan Hussain, and Pravin U Dugel MD : https://www.tandfonline.com/eprint/Eh34pFrtUA4ZVmjw3INp/full?target=10.1080/14712598.2019.1575358 Complement inhibition as a therapeutic strategy in retinal disorders (2019). Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opinion on Biological Therapy. Ahead of Print. Return to main website.